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Abstract
Despite the significant progress in managing patients infected with HIV through the development of Highly Active
Anti-Retroviral Therapy (HAART), major challenges and opportunities remain to be explored. Of particular interest,
is the binding of glycoprotein 120 (gp120) to the primary cellular receptor Cluster of Differentiation 4 (CD4). In this
work we describe our two phased computational process to identify useful compounds capable of binding to the gp120
protein for therapeutic purposes. We identified 187 compounds from the literature that conform to active binding sites
on these proteins and use these as training/test sets. The data in the form of quantitative structure-activity relationships
(QSAR) is downloaded from the ZINC database and transformed using principal components analysis. In the first phase
we developed a Radial Basis Function neural network model that identifies potential inhibitors from a virtual screen of
a subset of the ZINC database. In the second phase we modelled the top performing compounds using the Discovery
Studio docking and screening software. By employing this approach, we identified that those compounds with a LogP
value of approx 2-4 performed well in the binding simulations while the lower scoring compounds do not bind well.
Keywords: HIV, gp120, CD4, QSAR, RBF, PCA
1. Introduction
The development of Highly Active Anti-Retroviral Ther-
apy (HAART) (a combinatorial regime in which one or
more of the three viral enzymes are targeted by the use
of three therapeutic agents) has transformed the life ex-
pectancy of HIV positive individuals but major challenges
remain to be solved [46]. Firstly, and perhaps most im-
portantly, due to the poor fidelity of replication observed
with retroviruses, they quickly develop resistance to an-
tiviral agents and hence treatment failure results. [9] Sec-
ondly, due to the current requirement of daily dosing with
HAART, it is imperative that agents have a good safety
profile, no drug interactions and are easily administered.
[25]. Thirdly, the issue of viral latency still needs to be
addressed [50]. In order to address these challenges, there
is a need to develop new agents and the targeting of viral
entry has emerged as a viable approach. Viral entry into
host cells is a complex phenomenon [16] involving many
steps operating in sequence. Initial contact with a host
cell by the virus is mediated via heparin sulfate [35] and
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leads to the specific interaction between the viral protein,
glycoprotein 120 (gp120) and the primary cellular receptor
Cluster of Differentiation 4 (CD4).
In this work we describe our approach to develop statis-
tical models to identify compounds that can bind to the
gp120 glycoprotein. Gp120 is derived from the heavily gly-
cosylated protein Env gp160 and contains five conserved
domains (C1-C5) and five variable loops (V1-V5). The
binding of gp120 to CD4 induces a significant conforma-
tional change in gp120 that facilitates receptor engagement
[19]. The binding to the chemokine co-receptor (CCR5 or
CXCR4) by gp120 exposes the fusion peptide gp41 which
tethers the viral and host membrane together. Following
the fusion of the two membranes, the viral capsid is re-
leased into the cytosol of the cell, where the virus begins
its replicative cycle.
Targeting the early stages of the replicative cycle is
attractive because it precedes cellular infection and two
agents are currently licensed; enfuvirtide [14] and maravi-
roc [30]. Over the last several years a number of papers
have been published that have indicated that gp120 has
the potential to be a good target to develop new anti-
HIV inhibitors and examples of both peptide and small
Preprint submitted to Elsevier April 3, 2020
Figure 1: gp120 (PDB code: 1G9M) A: View of full gp120 protein
(Chain G) in line view, with the defined binding site in ball and stick
view. B: View of the binding site only with labels of amino acid
residues defined within the binding sphere. C: View of the binding
site in CPK from a different angle, showing the Phe 43 pocket.
molecule inhibitors have been reported.
Several families of small molecule HIV-1 entry inhibitors
have been reported over the years. Bristol-Myers Squibb
(BMS) first introduced BMS-378806 but this compound
was later dropped due to unfavourable pharmacokinetic
properties and focus moved to BMS-626529 (and its pro-
drug, BMS-663068) [33]. The BMS-378806 family of in-
hibitory compounds are thought to operate in a concen-
tration dependent manner exhibiting multiple mechanisms
to inhibit HIV-1 entry [34].
NBD-556, the archetype of the NBD family of com-
pounds work by targeting the ‘Phe43 cavity’; binding of
NBD-556 in this highly conserved hydrophobic cavity in
gp120 generates a substantial conformational change in
the gp120 protein that in turn disrupts binding [55].
Owing to the well-defined nature of the Phe43 cavity,
we sought to develop a neural network model that could
identify potential inhibitors that display favorable physio-
chemical properties to interact with the Phe43 cavity from
a virtual screen of a subset of the ZINC database (three
datasets each containing 5000 compounds were selected for
the current work).
A quantitative structure activity relationship (QSAR)
is a mathematical relationship between the biological ac-
tivity and the chemical and geometric characteristics of
a molecular system to be used in predicting the activ-
ity of unknown compounds [12, 10]. QSAR modeling is
widely accepted across several diverse organizations such
as industry, academia and government departments world-
wide for modeling the biological and physical properties of
chemicals and compounds [17]. Computational modeling
of QSAR data requires different molecular properties and
structural fingerprints to be calculated and then one or
more of statistical analysis models are applied to deter-
mine the relation between the activity and the structural
features of these compounds in terms of equations that can
be used as activity prediction tools.
Remove invalid compounds 
Build LR, PLS, MLP, RBF, SVM and RF regression models 
QSAR structures 
   ZINC                    
START: Query literature 
based compounds 
Remove uninformative variables 
Perform PCA 
Deploy most accurate model on 
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List of candidate compounds 
Model the binding affinity using Discovery Studio 
Figure 2: Overview of workflow operation
The overall data flow is presented in figure 2, here we
show data access, manipulation and model building that
is consistent with the QSAR data format [54]. Compu-
tationally speaking, the analysis is a regression solution
whereby we model a continuous value (pIC50) as the de-
pendent variable, influenced by the QSAR variables. The
models are used to screen the ZINC database, models such
as linear regression, partial least squares, SVM, MLP, Ran-
dom Forest and RBFs are compared for accuracy but also
for the usefulness of the detected compounds they identify
from the ZINC database.
2. Related work
Previous work, which has seen drug development con-
centrate on targeting the interaction between gp120 and
the cellular CD4 receptor has mostly affected by the se-
quence variation degree of the V1/V2 variable regions
[29]. Thus, the diversity between different viral subtypes
in these regions in addition to the intra-patient variabil-
ity can negatively influence the efficacy of gp120-CD4 in-
hibitors [1]. Targeting the binding between the gp120 and
the co-receptors which is the next step and is mediated
by the conformational changes of gp120 especially V1 /V2
and V3, is theoretically expected to be less affected by the
sequence variability of the viral glycoproteins because it is
concerned with the host protein [22].
The use of virtual screening protocols in drug discov-
ery is well established and the Kaggle competition in 2012
is recognised as the first demonstration of the capabilities
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of Deep-Learning (DL) algorithms in the drug-discovery
sphere [20]. Following that initial study, DL algorithms
have been extended to explore a range of diverse QSAR
datasets with a view to predicating the physiochemical
properties of molecules and selecting molecules for partic-
ular protein targets. For example, Lusci et-al developed a
neural network model that could predict a range of molecu-
lar properties, including the aqueous solubility of drug-like
molecules [28]. Other algorithms that have been employed
include the use of partial Least square (PLS), multiple
linear regression (MLR), artificial neural networks (ANN)
and principal component or factor analysis (PCA/FA);
are all examples of the statistical procedures that are fre-
quently used for building a QSAR model [43].
3. Methods
We selected all of the known compounds (187 at
the time of this investigation) implicated in binding to
the gp120 protein from the literature using PubMed
[4, 31, 32, 39, 48, 49, 53, 51, 52]. The literature references
for the 187 compounds were manually checked to ensure
that the biological assays used to determine activity were
comparable and the activity range (measured as IC50
values) was between 0.0054nM and 65.8µM. These com-
pounds were downloaded from the ZINC database and di-
vided randomly into a train and test set split (75%/25%).
The ZINC database (http://zinc15.docking.org/) is a
useful repository of compound data of commercially avail-
able materials for virtual screening and contains over 350
million compounds in ready-to-dock formats [45, 21]. The
variables for each structure used in this study, both the
initial dataset of 187 compounds and each of the screening
batches (3x5000 batches of compounds labelled A,B and
C obtained from the Zinc database) were calculated using
the Molecular Operating Environment (MOE, version
2008.10; https://www.chemcomp.com/Products.htm)
software. The MOE software calculated a mixture
of both 2D and 3D descriptors for each compound
(http://www.cadaster.eu/sites/cadaster.eu/
files/challenge/descr.htm); the calculated variables were
further processed.
We used the R statistics software to transform and an-
alyze this data [37], other add-on packages included the
ChemmineR package for handling SDF files and analyzing
drug-like small molecule data[3]. We processed a matrix
of 187 compounds with 316 variables, this was further re-
duced by removing any variable containing more than 90%
zeros or ones (unlikely to be informative) leaving 269 vari-
ables. Principal components analysis (PCA) further trans-
formed the data into a smaller number of variables. We
kept 15 principal components containing 82% of the vari-
ance. The PCA data was scaled to unit variance before the
analysis. This avoids any variable from becoming too dom-
inant because of large magnitudes of their values. Detailed
graphical analysis of the PCA results was provided by the
FactomineR package[23]. Our R source code and data are
available from: https://github.com/kenmcgarry/QSAR-
hiv
3.1. Computational models for predicting activity
We built several regression models using Radial Basis
Function (RBF) networks, Random Forests(RF), Multi-
layer Perceptrons (MLP) and Support Vector Machines
(SVM), comparing their performance on the test data.
The SVM is well suited for regression problems and SVM’s
have been successfully applied in bioinformatics [11, 44].
RBF networks provide a local solution to linear and nonlin-
ear problems [26]. The MLP is the oldest and best known
of the techniques and has seen many applications in a wide
variety of fields [6]. Many improvements have been made
to the original MLP algorithm in terms of speed, accuracy
and memory storage [8]. We also trained Random Forests,
these are a supervised ensemble regression technique where
a group of weak models combine to form a powerful model
[7]. Several decision trees are created (hence a forest) with
random sampling used as the attribute to split on, there is
a direct correlation between the number of trees in the for-
est and the accuracy. Another important advantage of the
Random Forest method is that the predictor variables are
ranked according to importance using the Gini impurity
measure. The RBF and MLP proved to be the superior
models in detecting viable drug-like compounds. We de-
ployed the RBF to detect the potential compounds in the
three random datasets, using the RBF to detect the po-
tential compounds from each dataset (5000 each) selected
at random from the ZINC database.
The Radial Basis Function model outperformed the
other regression models when it came to identifying ‘drug-
like’ leads, and in the case of both test datasets, the top
ten compounds identified complied with Lipinski’s rules
[24]. The improved performance of the RBF (see figure
3a) can be explained by considering the loadings of the
terms in both PC1 and PC2; 31.3% of the variance that is
captured by PC1 generally relates to a molecule’s polarity
and based on the physiochemical properties of the target
site on gp120, molecules with a Log P in the range 2-4
exhibit favourable binding characteristics.
3.2. Measures for determining model goodness of fit
The quality measures used to evaluate the models in-
clude R2, MAE, RMSE and the Tropsha and Roy mea-
sures.
R-squared (R2) is a statistical measure accounting for
the proportion of the variance for a dependent variable
that’s explained by an independent variable or variables.
The R2 value is calculated by sum of squared residuals
(SSR) divided by the total sum of squares (SSTO). The
SSR are deviations predicted from actual empirical values
of data. It is a measure of the discrepancy between the
data and an estimation model. A small RSS values imply
a good fit of the model to the data. The SSTO is defined
as the sum of the squared differences, over all observations,












The mean absolute error (MAE) measures the differ-
ence between two variables. Where X and Y are variables
of paired observations we use for comparisons between
predicted and observed values. Roy, further explains the
MAE measures the actual prediction errors with respect to
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. (2)
The root mean squared error (RMSE) provides an in-
dication of how much error there is between two sets of
values. Like the other measures it compares a predicted






Where: P= Predicted and O= observed values.




r2 − r20). (4)
Where: r2 is the squared correlation coefficient between
observed and predicted values, r20, is the same parameter
but with the intercept set to zero. The Roy value should
be > 0.5 to confirm a good model [40, 41].





Where: similar to Roy measure, we have r2 is the
squared correlation coefficient between observed and pre-
dicted values, r20, is the same parameter but with the in-
tercept set to zero. The Tropsha measure should return a
value of < 0.1 to confirm a robust model [15, 2].
3.3. Molecular docking and molecular dynamics
The top ten performing compounds from from datasets
A,B and C were then screened using a standard molecular
docking platform via Discovery Studio 4.5. Docking cal-
culations were used to measure the binding affinity of the
test compounds towards the target protein [18]. Owing to
the fact that the viral glycoprotein gp120 is highly flexible
[47], both the open (unbound) and closed (bound) forms
were employed in the docking study. The open and closed
forms were represented by the PDB-ID 4RZ8 and 1G9M
respectively, and were downloaded from the protein data
bank (www.rcsb.org) [5], having a resolution of 1.9 Å for
4RZ84 and 2.2 Å for 1G9M [13]. The docking calculations
were validated by comparing the resulting docking energies
of the selected compounds with that of NBD-556 which is
a potent HIV-1 entry inhibitor [36].
For the docking simulation, water of crystallization was
removed and protonation was carried out for both forms of
the target protein. The active site was determined using
the volume occupied by an existing co-crystalized ligand
in case of 4RZ8N protein, while the Phe43 amino acid
was used to generate a sphere with a diameter of 10 Å
to represent the active site in the 1G9M protein struc-
ture [38]. Each compound was energy minimized, and the
top 10 conformations generated during the docking pro-
cess. The docked ligands were ranked and evaluated using
the bonding interactions with the residues of the active
site and their consensus scores which were calculated for
each compound using the Consensus Score protocol [27].
Following docking of all compounds, CDOCKER energy
and the CDOCKER INTERACTION energy scores of all
compounds have been compared in order to evaluate the
docking potential with the target viral protein.
Molecular dynamics simulations were undertaken for
one of the top performing leads, CMP2463 in order to
assess the validity of the binding mode using Discovery
Studio 3.1. The ligand was selected for the molecular dy-
namics on a pre-equilibrated molecule. The protein-ligand
system was not solvated. Prior to running the simula-
tions, (CHARMm) energy minimisations were run using
the Standard Dynamics Cascade. The open form of the
protein was used for the study.
4. Results
In figure 3b we present the results of the PCA analy-
sis, 41.2% of the variance is captured by PC1 and 13.2%
by PC2, thereafter each PC provides a smaller percent-
age of the variance as indicated by the screeplot. The
biplot shows the loading’s of each variable across PC1 and
PC2, the variables colored cyan (found mainly in center
of the plot) have low contributions while those colored
red/orange indicate high contributions. The arrows point
in the direction of the variables when they projected into
the x-y axis of the biplot. The larger the arrow, the larger
the loading of that particular variable on the first two prin-
cipal components and hence its importance. Like all bi-
plots, we are assuming both PC1 and PC2 contain a suffi-
cient amount of the variance together (54%) to provide a
meaningful visual representation of the structure of cases
(compounds) and variables.
We trained an RBF neural network using the PCA re-
duced data. The RBF networks structure was determined
empirically using 10-fold CV and with repeats until the
optimum model was produced with a σ of 10, this is high-
lighted in figure 5.
Examining Figure 3b and table 2 it is evident that the
RBF network has clustered a lot of terms that describe
the ’polarity’ of a molecule. Relating this to the character
of the gp120 binding pocket, the more hydrophobic, the











































































































































































































































































































Figure 3: Details of PCA analysis, 15 principal components were retained, explaining 82% of variance
appears to be significantly better at selecting ’drug-like’
molecules compared to the other models.
Table 1: Variable contributions to PC1
Descriptor Definition
Vsurf-CW3 Capacity factor at -1.0
Logp.o.w. Log octanol/water partition coefficient
Slogp Log octanol/water partition coefficient
ASA-H Total hydrophobic surface area
Vsurf-CW1 Capacity factor at -0.2
Q-VSA-HYD Total hydrophobic vdw surface area
Vsurf-CW2 Capacity factor at -0.5
Vsurf-CW4 Capacity factor at -2.0
Vsurf-D6 Hydrophobic volume at -1.2
Vsurf-D5 Hydrophobic volume at -1.0
POEO-VSA+1 Total negative 1 vdw surface area
FASA-P Fractional polar surface area
FASA-H Fractional hydrophobic surface area
Q-VSA-FHYD Fractional hydrophobic vdw surface area
Q-VSA-FPOL Fractional polar vdw surface area
PEOE-VSA-FPNEG Fractional polar negative vdw surface area
Vsa-hyd VDW hydrophobe surface area
Chi1-C Carbon connectivity index (order 1)
Chi1v-C Carbon valence connectivity index (order 1)
PEOE-VSA-FPOL Fractional polar vdw surface area
In figure 6 the residual error plot is shown, residual plots
are useful for checking regression models performance and
to indicate outlier values. In the top left we have the cu-
mulative distribution plot, this is the proportion of values
less than or equal to residual errors (on x-axis). It shows
an increasing step function that has a vertical jump of 1/N
at each value of x-axis equal to an observed value.
In the top right diagram we have the residual errors
plotted against the fitted data points. The residuals on the
y axis and fitted values (estimated responses) on the x axis.
This plot is useful for highlighting outliers, non-linearity
and unequal error variances. It indicates that compounds
32, 56 and 106 are marginally different compared with the
Table 2: Variable contributions to PC2
Descriptor Definition
chi1 Aromatic connectivity index (order 1)
a-heavy Number of heavy atoms
VDisMa Vertex distance magnitude index
VAdjEq Vertex adjacency information (equal)
chi0 Aromatic connectivity index (order 0)
Kier1 First kappa shape index
VAdjMa Vertex adjacency information (mag)
b-heavy Number of heavy-heavy bonds
Kier2 Second kappa shape index
vsurf-W1 Hydropholic volume at -0.2
vDistEq Vertex distance equality index
Zagreb Zagreb index
PM3-Eele Electronic energy (Kcal/mol)
weinerPath Weiner path number
weinerPol Weiner polarity number
PC- Total negative partial charge
PC+ Total positive partial charge
Vsurf-Wp1 Polar volume at -0.2
other compounds in the training data. However, the data
points are trended around the 0 line which indicates that
the assumption that the relationship is linear is reasonable.
The residuals also follow a horizontal shaped cloud around
the zero line which in indicates the variances of the error
terms are equal.
In the bottom left we have the residual Q-Q plot, if
the data are normally distributed the residuals follow a
straight line on this plot and for the RBF model it is a
good indication they are normally distributed. We can see
the same outliers (compounds 32, 56 and 106 identified).
In the bottom right we have the absolute residual errors
plotted against the fitted values, here the larger the resid-
ual absolute value becomes, the further that the point lies







































Figure 4: Top 20 contributing compounds and variables.
4.1. Database screening using trained computational mod-
els
All models were developed using 10-fold cross validation
with repeats enabling a range of parameters (depending
on the model) that were automatically tuned for optimum
performance.
In table 3 we compare the RMSE accuracy and MAE
accuracy on the training data, this approach is often used
in QSAR analysis to ensure that a good model is the-
oretically possible. These values are derived by passing
the training data through the model, hence accuracies are
higher than those using only the test data. The Roy and
Tropsha measures require the test data to be employed
and hence cannot appear in table 3.
Table 3: Model accuracy on training data
Model R2 RMSE MAE
RBF 0.90 0.81 0.56
MLP 1.0 0.0003 0.001
SVM 0.93 2.33 1.85
Random Forest 0.97 0.51 0.39
Partial Least Squares 0.70 1.29 1.05
Linear Regression 0.70 1.28 1.05
In table 4 we compare the RMSE accuracy and MAE
accuracy on the test data. The Partial Least Squares and
the linear regression models had the least accuracy and
they identified compounds that were clearly unsuitable as
drug-targets. Slightly better results were returned by the
Random Forest and SVM models. Only the RBF and MLP
neural network had succeeded in identifying viable com-
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Figure 5: Cross validation tuning of σ parameter for RBF network
of 15 input units with 150 basis units, the output layer
was a single neuron. The final architecture of the MLP
consisted of 25 units in the 1st hidden layer and the 2nd
hidden layer with 21 units. One output unit was used.
The RBF network used the Kernel-Based Regularized
Least Squares (KRLS) which enables the solution of re-
gression and classification problems. KRLS finds the best
fitting function by minimizing a regularization problem
with a squared loss. This is achieved by using Gaussian
Kernels as the radial basis functions. KRLS reduces bias
by adapting the functional form from the data and also
allows for interpretability and inference in ways similar to
ordinary regression models.
Table 4: Model accuracy on test data
Model R2 RMSE MAE Roy Tropsha
RBF 0.63 1.18 0.94 0.56 0.02
MLP 0.47 2.06 1.62 0.22 0.57
SVM 0.54 1.12 0.89 0.22 0.65
Random Forest 0.52 1.35 0.98 0.22 0.65
Partial Least Squares 0.47 1.40 1.10 0.39 0.0
Linear Regression 0.47 1.41 1.11 0.38 0.0
Having constructed and tested the regression models us-
ing the 187 literature curated compounds we downloaded
three random datasets, labeled A, B, and C (each con-
taining 5000 compounds) from the ZINC database web-
site (http://zinc15.docking.org) and used the models to
predict their activity against the gp120-CD4 interaction.
For each of the datasets A,B and C, the compounds were
ranked according to their predicted activity, with the top
10 compounds from A,B and C indicated in table 5.
Examining table 5 the CMP column is our own inter-
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PIC50     type=raw     train.formula(form=form, data=trainingdata, method="krlsRadial", trCo...
Figure 6: Residual plot of RBF network performance
nal identification for the compounds. The expected pIC50
column refers to the negative log of the IC50 value in mo-
lar, generally speaking the larger the pIC50 value the more
useful/powerful the compound will be. The next column
gives the generally accepted identification from the ZINC
database. The LogP column provides predicted value for
each compound and is one of Lipinski’s rules [24]. More
specifically, it is used to give an indication of the lipophilic-
ity of the compounds, and can be defined as the ratio of
the concentration of the unionized compound at equilib-
rium. A negative value for LogP suggests the compound
is more hydrophilic. Values for logP approx zero, indi-
cates the compound is equally partitioned between the
lipid and aqueous phases. Whereas, a positive LogP value
suggests a higher concentration in the lipid phase. The
CDOCKER energy column provides information gener-
ated by the compound to protein docking process. It is
an estimation based upon the internal ligand strain en-
ergy and receptor-ligand interaction energy. Similarly, the
next column describes the CDOCKER interaction energy,
large values implies a greater potential for binding between
the protein and the ligand. The CDocker E (1G9M) and
Interaction (1G9M) columns are diagnostic outputs used
to measure the binding affinity of the test compounds to-
wards the target protein.
In general, the docking energies of the top 30 compounds
(comprised of the top 10 from batches A-C) were much
higher (high CDOCKER energy) than that of NBD-556
against both the open and closed forms of the viral glyco-
protein gp120. For example, compound 2463 has an en-
ergy score (CDOCKER energy)= -49.41 kcal mol−1 while
the NBD-556 compound has a CDOCKER energy= -38.96
kcal mol−1 (Note: the more negative binding energy, the
tighter the binding between the ligand and the biological
target). Figure 8a shows the binding interactions observed
with CMP2463.
To assist validation in the docking model we also se-
lected compounds with low scores from the RBF network
model. These compounds demonstrated very low bind-
ing affinity compared with the top scoring compounds and
thus provides greater confidence in our model.
To further confirm the potential inhibitory potential of
CMP2463, a MD simulation employing the open form of
gp120 was run and the data from the last 1 ns of the equi-
librium stage is shown in Table 6, where Time is nanosec-
onds; Energy values are kcal mol−1; Temperature values
listed in kelvin.
5. Discussion
The RBF model outperformed the other regression mod-
els when it came to identifying ’drug-like’ leads, and in the
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Table 5: Top ten compounds identified by the RBF model from data sets A, B and C. All CDOCKER energy values are in kcal ·mol − 1.
CDOCKER energy relates to the energy from the protein-ligand interaction and the CDOCKER interaction energy relates to the nonbonding
interaction energy from the protein-ligand interaction. Both parameters were calculated via the Discovery Studio standard protocols.
DATA SET A
Compound Predicted pIC50 Zinc Database ID CDOCKER Energy CDOCKER.Interaction.Energy ALogP Binding Energy
CMP1927 11.238 ZINC39971756 -18.270 -32.980 2.993 -52.755
CMP910 11.155 ZINC15784661 -24.768 -36.179 3.350 -48.050
CMP2554 11.072 ZINC79851413 -19.672 -31.580 3.264 -44.596
CMP3133 11.069 ZINC15784696 -28.888 -38.339 3.813 -55.536
CMP1537 10.958 ZINC73744134 -26.313 -35.303 3.489 -46.425
CMP1348 10.948 ZINC79851405 -11.084 -38.433 1.849 -32.172
CMP466 10.943 ZINC73744123 -26.013 -34.974 3.489 -72.320
CMP2067 10.917 ZINC79018773 -11.100 -34.444 0.680 -118.778
CMP1812 10.876 ZINC51150530 -25.562 -40.271 1.019 -115.241
CMP2385 10.858 ZINC51150533 -26.757 -40.869 1.019 -120.310
DATA SET B
Compound Predicted pIC50 Zinc Database ID CDOCKER Energy CDOCKER.Interaction.Energy ALogP Binding Energy
CMP2783 10.919 ZINC86366942 -29.716 -34.218 1.080 -113.818
CMP3191 10.897 ZINC93999713 -14.306 -40.833 1.064 -129.116
CMP582 10.825 ZINC72246203 -28.996 -42.549 1.196 -107.617
CMP4158 10.825 ZINC72773347 -16.252 -44.047 1.977 -137.570
CMP3257 10.751 ZINC94700306 -35.089 -35.816 -0.238 -139.741
CMP785 10.719 ZINC46503106 -26.045 -35.361 -0.160 -116.005
CMP4964 10.704 ZINC93974761 -25.594 -26.734 1.572 -53.793
CMP3158 10.671 ZINC93604656 -11.940 -29.602 1.416 -107.094
CMP2413 10.669 ZINC74334516 -17.550 -37.770 1.200 -130.524
CMP4271 10.668 ZINC77420512 -26.012 -33.503 -0.306 -140.540
DATA SET C
Compound Predicted pIC50 Zinc Database ID CDOCKER Energy CDOCKER.Interaction.Energy ALogP Binding Energy
CMP2463 10.979 ZINC11911190 -27.746 -49.410 2.146 -138.228
CMP660 10.948 ZINC11911189 -27.750 -51.580 2.146 -135.031
CMP3106 10.902 ZINC67012458 -18.542 -46.609 2.193 -119.507
CMP4524 10.856 ZINC02493577 -25.096 -41.377 2.893 -107.055
CMP1193 10.843 ZINC58295890 -18.598 -40.037 1.214 -122.927
CMP1321 10.830 ZINC67012457 -17.906 -45.928 2.193 -121.347
CMP945 10.773 ZINC37210364 -14.861 -32.838 1.476 -107.686
CMP3058 10.673 ZINC05656549 -14.498 -32.645 3.389 -91.071
CMP5 10.605 ZINC81998334 -8.132 -41.977 0.434 -133.282
CMP2744 10.598 ZINC37210365 -13.937 -31.316 1.476 -129.768
case of all three test datasets, the top ten compounds iden-
tified complied with Lipinski’s rule. The improved perfor-
mance of the neural network can be explained by consid-
ering the loading’s of the terms in both PC1 and PC2;
31.3% of the variance that is captured by PC1 generally
related to a molecule’s polarity and based on the physic-
ochemical properties of the of the target site on gp120,
molecules with a logP in the range 2-4 exhibit favorable
binding characteristics.
The top 10 compounds from the analysis of each of the
batches A-C all targeted the highly conserved Phe43 cav-
ity and displayed very favourable binding interactions with
the key amino acid residues; key amino acid residues in-
clude Trp112, Val255, Ser 256, Thr 257, Asn425, Met426,
Trp427, Val430, Gly473, Met475.
For example, CMP4364 (Figure 7), like NBD-556 can
be seen to interact with several key amino acid residues
including Val 255, Tyr 384, Asp368, Asn425 and Trp427;
also, like NBD-556, the basic amino moiety forms a hy-
drogen bond to Asp368. In addition, the hydrophobic aro-
matic ring of CMP4364 pushes deep into the hydrophobic
core of the Phe 43 pocket. Also of note with CMP4364
are the presence of two amine moieties in the molecule
which would allow the preparation of pharmaceutical salts
and hence improve the water solubility of CMP4364. This
point is significant since although NBD-556 possess good
antiviral activity, it has poor water solubility [55].
Compound 1321 (Figure 8) exhibits extensive binding
interactions within the Phe43 cavity; the chlorosubstituted
aryl ring makes a number of hydrophobic interactions with
the following hydrophobic residues, Val255, Phe382, Ile424
and Trp427. In addition, several hydrogen bonds are
formed with residues Asp368, Glu370 and Asn425. Com-
pound 2463 is one of the best performing compounds iden-
tified by the RBF model, making many of the same binding
interactions in the Phe43 cavity as is seen with NBD-556;
Asp368, Asn425, Trp427 and Gly473.
Figure 9 shows the binding interactions of CMP2463
with the Phe43 cavity; the substituted benzyl ring has
an electrostatic interaction with Asp368; the substituted
piperidine ring has a Van der Waals type interaction with
Ile371; the triazole ring makes π stacking and π−π stack-
ing interactions with Trp427 and Met426 respectively; the
two methyl groups of the amide make a number of hy-
drophobic based interactions with Ile424,Phe382, Trp112,
Ser256, Trp427 and Val255.
A MD simulation, which allows the calculation of the
empirical free energy of binding was run for one of the
top performing compounds identified, CMP2463 (Table 6);
total binding energy from the docking simulation was -
138.228 kcal mol−1 versus an average value of -150.2354
kcal mol−1 for the stable conformation generated during
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(a) Schematic presentation of interactions between compound 4364 and
residues of gp120 protein (PDB ID: 4RZ8)
(b) Molecular modelling image of compound 4364 showing
bonding interactions and lowest energy conformation.
Figure 7: Molecular modelling images of compound 4364 generated in Discovery Studio.
Table 6: Binding Free Energy of CMP2463 with gp120 calculated by MD simulation. Key: Time is nanoseconds; Energy values are kcal/mol;



















4100 4.1 150.1769 52.2287 97.9481 307.4 22.5481 31.2062 24.8694 1.681 -4.6673
4200 4.2 150.3716 46.0512 104.3204 271.041 25.8667 33.7893 23.8902 1.4811 -3.072
4300 4.3 150.4226 40.1788 110.2438 236.478 26.5536 37.3468 25.4329 1.3542 -3.7465
4400 4.4 149.8507 58.9242 90.9265 346.807 20.7757 26.04 24.245 0.8982 -3.9755
4500 4.5 150.1733 45.0114 105.1618 264.922 22.5248 36.7968 24.8954 0.8107 -3.5466
4600 4.6 150.1489 53.7562 96.3927 316.39 20.4215 32.7107 23.8365 1.4913 -5.3857
4700 4.7 150.2818 51.8958 98.386 305.44 21.1674 35.8577 22.5301 1.5722 -6.0508
4800 4.8 150.3356 49.5212 100.8144 291.464 22.7718 39.3319 22.4577 1.0156 -6.7101
4900 4.9 150.6016 42.4288 108.1728 249.721 27.5421 36.0916 23.7647 0.6644 -3.6401
5000 5.0 149.9905 54.5455 95.445 321.036 17.3497 34.3373 22.7916 2.6686 -3.4528
the last 1 ns of the MD simulation.
Further modelling work is planned for the best perform-
ing compounds identified by the RBF model in order to de-
velop a SAR model for each potential lead. However, based
on the observed similarity of binding between our leads
and NBD-556 with the Phe43 cavity, we speculate that
our compounds could also act as competitive inhibitors
for CD4 and hence prevent cell-virus fusion.
6. Conclusions
It is increasingly the case that modern drug discovery
relies on the ability to rapidly run virtual high-throughput
screening programmes that can screen as much of chem-
ical space as the computing power will allow in order to
identify new potential leads. It is therefore desirable to
be able to pre-filter the large datasets involved and hence
we have developed an RBF model that can be used to fil-
ter large structural databases such as the ZINC database
in order to identify leads that target gp120. One of the
main advantages of the RBF model we have developed is
that once trained, it is using an additional and different
set of algorithms compared to many of the commercially
available molecular modelling packages to search chemi-
cal space (this should help to improve the diversity of the
searches). We have also demonstrated that the RBF model
is particularly adept at selecting ‘drug- like’ molecules that
comply with Lipinski’s rules and also target the Phe43
cavity and indeed, many of the top leads showed excel-
lent binding to the target and made a number of binding
interactions that mirrored those seen with NBD556. The
ability to target HIV-1 gp120 and hence block viral entry
is an attractive point of attack since such agents also offer
the possibility of opening the virus via epitope exposure,
to an immune response involving broadly neutralizing an-
tibodies.
We are currently synthesising a number of the leads
identified for biological screening and will report our re-
sults soon.
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(a) Schematic representation of compound 1321 bound in the Phe43 cavity
showing the key bonding interactions (PDB ID: 4RZ8)
(b) Molecular modelling image for compound 1321 binding
to gp120 indicating both the key bonding interactions and
the lowest energy conformation (PDB ID: 4RZ8)
Figure 8: Molecular modelling images of compound 1321 generated in Discovery Studio.
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